These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 3091692)

  • 21. Graft-facilitating doses of ex vivo activated gammadelta T cells do not cause lethal murine graft-vs.-host disease.
    Drobyski WR; Majewski D; Hanson G
    Biol Blood Marrow Transplant; 1999; 5(4):222-30. PubMed ID: 10465102
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Selective elimination of alloreactive donor T cells attenuates graft-versus-host disease and enhances T-cell reconstitution.
    Gendelman M; Yassai M; Tivol E; Krueger A; Gorski J; Drobyski WR
    Biol Blood Marrow Transplant; 2003 Dec; 9(12):742-52. PubMed ID: 14677113
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Graft-vs.-host and graft-vs.-leukemia reactions after delayed infusions of donor T-subsets.
    Johnson BD; Becker EE; Truitt RL
    Biol Blood Marrow Transplant; 1999; 5(3):123-32. PubMed ID: 10392958
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Anti-IL-4 antibody prevents graft-versus-host disease in mice after bone marrow transplantation. The IgE allotype is an important marker of graft-versus-host disease.
    Ushiyama C; Hirano T; Miyajima H; Okumura K; Ovary Z; Hashimoto H
    J Immunol; 1995 Mar; 154(6):2687-96. PubMed ID: 7876541
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Peripheral tolerance to host minor histocompatibility antigens in radiation bone marrow chimeras abrogates lethal GVHD while preserving GVL effect.
    de la Selle V; Miconnet I; Gilbert D; Bruley-Rosset M
    Bone Marrow Transplant; 1995 Jul; 16(1):111-8. PubMed ID: 7581109
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A semi-pharmaceutical approach for the preparation of an anti-IL2 receptor monoclonal antibody in the treatment of acute GvHD in a multicentric study.
    Wijdenes J; Beliard R; Muot S; Herve P; Peters A
    Dev Biol Stand; 1990; 71():103-11. PubMed ID: 2205522
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A locus on chromosome 2 influences the development of acute graft-versus-host disease in a murine model.
    Harper JM; Slayback DL; Dobkins JA; Allen RD
    Bone Marrow Transplant; 1999 Jun; 23(11):1183-90. PubMed ID: 10382959
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prevention of lethal graft-versus-host disease in mice by monoclonal antibodies directed against T cells or their subsets. I. Evidence for the induction of a state of tolerance based on suppression.
    Knulst AC; Tibbe GJ; Noort WA; Bril-Bazuin C; Benner R; Savelkoul HF
    Bone Marrow Transplant; 1994 Mar; 13(3):293-301. PubMed ID: 8199571
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Use of monoclonal antibodies in vivo as a therapeutic strategy for acute GvHD in matched and mismatched bone marrow transplantation.
    Herve P; Bordigoni P; Cahn JY; Flesch M; Tiberghien P; Racadot E; Milpied N; Bergerat JP; Plouvier E; Roche C
    Transplant Proc; 1991 Feb; 23(1 Pt 2):1692-4. PubMed ID: 1989333
    [No Abstract]   [Full Text] [Related]  

  • 30. Vbeta spectratype analysis reveals heterogeneity of CD4+ T-cell responses to minor histocompatibility antigens involved in graft-versus-host disease: correlations with epithelial tissue infiltrate.
    Friedman TM; Statton D; Jones SC; Berger MA; Murphy GF; Korngold R
    Biol Blood Marrow Transplant; 2001; 7(1):2-13. PubMed ID: 11215694
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Alloreactivity and the predictive value of anti-recipient specific interleukin 2 producing helper T lymphocyte precursor frequencies for alloreactivity after bone marrow transplantation.
    Russell CA
    Dan Med Bull; 2002 May; 49(2):89-108. PubMed ID: 12064093
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treatment of steroid-resistant graft-versus-host disease after allogeneic bone marrow transplantation with anti-CD3/TCR monoclonal antibodies.
    Hebart H; Ehninger G; Schmidt H; Berner B; Reuss-Borst M; Waller HD; Müller CA; Einsele H
    Bone Marrow Transplant; 1995 Jun; 15(6):891-4. PubMed ID: 7581087
    [TBL] [Abstract][Full Text] [Related]  

  • 33. IL-2 inhibits early increases in serum gamma interferon levels associated with graft-versus-host-disease.
    Szebeni J; Wang MG; Pearson DA; Szot GL; Sykes M
    Transplantation; 1994 Dec; 58(12):1385-93. PubMed ID: 7809932
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Interleukin 2 receptor dysfunction in mice undergoing a graft-vs-host reaction.
    Joseph LJ; Iwasaki T; Malek TR; Shearer GM
    J Immunol; 1985 Sep; 135(3):1846-50. PubMed ID: 3926888
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Lymphohematopoietic graft-vs.-host reactions can be induced without graft-vs.-host disease in murine mixed chimeras established with a cyclophosphamide-based nonmyeloablative conditioning regimen.
    Pelot MR; Pearson DA; Swenson K; Zhao G; Sachs J; Yang YG; Sykes M
    Biol Blood Marrow Transplant; 1999; 5(3):133-43. PubMed ID: 10392959
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Nonmitogenic anti-CD3F(ab')2 fragments inhibit lethal murine graft-versus-host disease induced across the major histocompatibility barrier.
    Blazar BR; Taylor PA; Snover DC; Bluestone JA; Vallera DA
    J Immunol; 1993 Jan; 150(1):265-77. PubMed ID: 8417127
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A new marrow T cell depletion method using anti-CD6 monoclonal antibody-conjugated magnetic beads and its clinical application for prevention of acute graft-vs.-host disease in allogeneic bone marrow transplantation: results of a phase I-II trial.
    Sao H; Kitaori K; Kasai M; Shimokawa T; Kato C; Yamanishi H; Ueda R; Morishima Y
    Int J Hematol; 1999 Jan; 69(1):27-35. PubMed ID: 10641440
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Amelioration of acute GVHD disease and reestablishment of tolerance by short term treatment with anti TCR antibody.
    Ascher NL
    Liver Transpl Surg; 1995 Jul; 1(4):257-8. PubMed ID: 9346577
    [No Abstract]   [Full Text] [Related]  

  • 39. Interleukin-1 or tumor necrosis factor-alpha antagonists do not inhibit graft-versus-host disease induced across the major histocompatibility barrier in mice.
    Vallera DA; Taylor PA; Vannice JL; Panoskaltsis-Mortari A; Blazar BR
    Transplantation; 1995 Dec; 60(11):1371-4. PubMed ID: 8525541
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effective graft-versus-leukemia effects independent of graft-versus-host disease after T cell-depleted allogeneic bone marrow transplantation in a murine model of B cell leukemia/lymphoma. Role of cell therapy and recombinant IL-2.
    Weiss L; Lubin I; Factorowich I; Lapidot Z; Reich S; Reisner Y; Slavin S
    J Immunol; 1994 Sep; 153(6):2562-7. PubMed ID: 8077666
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.